SGLT2 inhibitor originally developed for type 2 diabetes. Blocks glucose reabsorption in kidneys, creating a mild glucose deficit that activates AMPK and mimics caloric restriction. Extended lifespan in male mice in the ITP.
Interactions
Potentiates hypoglycemia with insulin/sulfonylureas
Increases risk of genital mycotic infections
May interact with loop diuretics
Contraindications
Type 1 diabetes (DKA risk)
Severe renal impairment (eGFR <30)
History of recurrent UTIs
Key Papers
Miller et al. 2020 - Canagliflozin extends lifespan in male mice (Aging Cell)
Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.
Should Canagliflozin Be in Your Stack?
Take the free assessment and get personalized recommendations based on your biology and goals.